Loading…
Employees: 939
Size Shanghai Jiaoda Onlly (600530.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $464M, the 4044th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥4.02 on 6 Nov 2026.
Performance Over six months the shares fell 22.2%, against -16.4% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 2.3% over the last twelve months (peer median -6.3%); the operating margin is -2.2% (peer median 4.4%).
Valuation It trades at 10.4× enterprise value to sales against a peer median of 4.4× (6th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.0 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥305M | CN¥313M | CN¥324M | CN¥295M | CN¥376M |
| Revenue growth | — | -3% | +10% | -21% | — |
| Gross profit | CN¥125M | CN¥88.6M | CN¥92.6M | CN¥65.5M | CN¥145M |
| EBITDA | n/a | CN¥57.2M | CN¥69.3M | CN¥30.3M | -CN¥287M |
| Net income | -CN¥16.9M | CN¥3.49M | CN¥30.5M | -CN¥35.1M | -CN¥499M |
| Free cash flow | CN¥37.2M | CN¥20.1M | CN¥58.2M | CN¥46.1M | CN¥72.5M |
| Capital expenditure | CN¥3.50M | CN¥2.94M | CN¥5.48M | CN¥9.55M | CN¥25.8M |
| Total debt | CN¥155M | CN¥160M | CN¥158M | CN¥209M | CN¥277M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600530.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.9% | -11.4% | highest of 20 |
| 6-month return | -22.2% | -16.4% | 6th lowest of 20 |
| Distance from 52-week high | -56.3% | -40.7% | 3rd lowest of 20 |
| Revenue growth (TTM) | -2.3% | -6.3% | 9th highest of 21 |
| Operating margin | -2.2% | 4.4% | 9th lowest of 21 |
| EV / Sales | 10.4× | 4.4× | 6th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 33.5% | 7.1% | 3rd most demanding of 10 |
| Growth delivered (Del g) | -0.9% | +1.0% | 4th lowest of 10 |
| Hurdle (Req g minus delivered) | +34.5 pp | +3.8 pp | 3rd most demanding of 10 |
| ROIC minus cost of capital | +0.0 pp | -2.5 pp | 7th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 0.2× | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | 4.4× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | 10.5× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | 6.0× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | 4.3× | 23.7% | +28.2% |